1. Kopitnik NL, Huecker MR. Opioid prescribing. In: StatPearls
[Internet]. Treasure Island, FL: StatPearls Publishing; 2024.
Available from: https://www.ncbi.nlm.nih.gov/books/
NBK551720/. Updated July 21, 2023.
2. Kumar R, Viswanath O, Saadabadi A. Buprenorphine. In:
StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing;
2023. Available from: https://www.ncbi.nlm.nih.gov/books/
NBK459126/. Updated November 30, 2023.
3. Theisen K, Jacobs B, Macleod L, Davies B. The United States
opioid epidemic: a review of the surgeon’s contribution to it
and health policy initiatives. BJU Int. 2018;122(5):754-9. doi:
10.1111/bju.14446.
4. Keyes KM, Rutherford C, Hamilton A, Barocas JA, Gelberg
KH, Mueller PP, et al. What is the prevalence of and trend
in opioid use disorder in the United States from 2010 to
2019? Using multiplier approaches to estimate prevalence
for an unknown population size. Drug Alcohol Depend Rep.
2022;3:100052. doi: 10.1016/j.dadr.2022.100052.
5. Dydyk AM, Jain NK, Gupta M. Opioid use disorder. In:
StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing;
2024. Available from: https://www.ncbi.nlm.nih.gov/books/
NBK553166/#:~:text = Opioid%20use%20disorder%20
(OUD)%20is,syndrome%20when%20opioids%20are%20
discontinued. Updated January 17, 2024.
6. Toce MS, Chai PR, Burns MM, Boyer EW. Pharmacologic
treatment of opioid use disorder: a review of pharmacotherapy,
adjuncts, and toxicity. J Med Toxicol. 2018;14(4):306-22. doi:
10.1007/s13181-018-0685-1.
7. Mancher M, Leshner AI. The effectiveness of medication-based
treatment for opioid use disorder. In: Medications for Opioid
Use Disorder Save Lives [Internet]. Washington, DC: National Academies Press (US); 2019. Available from: https://www.ncbi.
nlm.nih.gov/books/NBK541393/#:~:text = In%20persons%20
wi th%20OUD%2C%20methadone,heroin%2C%20
codeine%2C%20and%20oxycodone.
8. Marwah R, Coons C, Myers J, Dumont Z. Buprenorphinenaloxone
microdosing: tool for opioid agonist therapy
induction. Can Fam Physician. 2020;66(12):891-4. doi:
10.46747/cfp.6612891.
9. Comparison table: some drugs for maintenance treatment of
opioid use disorder. Med Lett Drugs Ther. 2023;65(1684):e144-
5. doi: 10.58347/tml.2023.1684b.
10. Menard S, Jhawar A. Microdose induction of buprenorphinenaloxone
in a patient using high dose methadone: a case
report. Ment Health Clin. 2021;11(6):369-72. doi: 10.9740/
mhc.2021.11.369.
11. Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger
B, Walter M, et al. Use of microdoses for induction of
buprenorphine treatment with overlapping full opioid agonist
use: the Bernese method. Subst Abuse Rehabil. 2016;7:99-
105. doi: 10.2147/sar.S109919.
12. Kahan M, Marion-Bellemare L, Samson J, Srivastava A.
“Macrodosing” sublingual buprenorphine and extendedrelease
buprenorphine in a hospital setting: 2 case
reports. J Addict Med. 2023;17(4):485-7. doi: 10.1097/
adm.0000000000001148.
13. Raheemullah A, Benhamou OM, Kuo J, Lembke A.
Buprenorphine microdosing cross tapers: a time for change.
Int J Environ Res Public Health. 2022;19(24):16436. doi:
10.3390/ijerph192416436.
14. Spadaro A, Long B, Koyfman A, Perrone J. Buprenorphine
precipitated opioid withdrawal: prevention and management
in the ED setting. Am J Emerg Med. 2022;58:22-6. doi:
10.1016/j.ajem.2022.05.013.
15. Antoine D, Huhn AS, Strain EC, Turner G, Jardot J, Hammond
AS, et al. Method for successfully inducting individuals who
use illicit fentanyl onto buprenorphine/naloxone. Am J Addict.
2021;30(1):83-7. doi: 10.1111/ajad.13069.
16. Rudolf GD. Buprenorphine in the treatment of chronic pain.
Phys Med Rehabil Clin N Am. 2020;31(2):195-204. doi:
10.1016/j.pmr.2020.02.001.
17. Herring AA, Vosooghi AA, Luftig J, Anderson ES, Zhao X,
Dziura J, et al. High-dose buprenorphine induction in the
emergency department for treatment of opioid use disorder.
JAMA Netw Open. 2021;4(7):e2117128. doi: 10.1001/
jamanetworkopen.2021.17128.
18. De Aquino JP, Parida S, Sofuoglu M. The pharmacology of
buprenorphine microinduction for opioid use disorder. Clin
Drug Investig. 2021;41(5):425-36. doi: 10.1007/s40261-021-
01032-7.
19. Robbins JL, Englander H, Gregg J. Buprenorphine microdose
induction for the management of prescription opioid
dependence. J Am Board Fam Med. 2021;34(Suppl):S141-6.
doi: 10.3122/jabfm.2021.S1.200236.
20. Adams KK, Machnicz M, Sobieraj DM. Initiating buprenorphine
to treat opioid use disorder without prerequisite withdrawal: a
systematic review. Addict Sci Clin Pract. 2021;16(1):36. doi:
10.1186/s13722-021-00244-8.
21. Greenwald MK, Herring AA, Perrone J, Nelson LS, Azar P.
A neuropharmacological model to explain buprenorphine
induction challenges. Ann Emerg Med. 2022;80(6):509-24.
doi: 10.1016/j.annemergmed.2022.05.032.
22. Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for
opioid use disorder: an overview. CNS Drugs. 2019;33(6):567-
80. doi: 10.1007/s40263-019-00637-z.
23. Weimer MB, Fiellin DA. Low- and very low-dose
buprenorphine induction: new(ish) uses for an old(ish)
medication? Addiction. 2022;117(6):1507-9. doi: 10.1111/
add.15799.
24. Zoorob R, Kowalchuk A, Mejia de Grubb M. Buprenorphine
therapy for opioid use disorder. Am Fam Physician.
2018;97(5):313-20.
25. Brar R, Fairbairn N, Sutherland C, Nolan S. Use of a novel
prescribing approach for the treatment of opioid use disorder:
buprenorphine/naloxone micro-dosing - a case series. Drug
Alcohol Rev. 2020;39(5):588-94. doi: 10.1111/dar.13113.
26. Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction
of buprenorphine/naloxone: a review of the literature. Am J
Addict. 2021;30(4):305-15. doi: 10.1111/ajad.13135.
27. Racha S, Buresh M, Fingerhood M. Pharmacotherapy
of opioid use disorder-update and current challenges.
Psychiatr Clin North Am. 2022;45(3):335-46. doi: 10.1016/j.
psc.2022.04.001.
28. Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp
BA, Ramsey KS. ASAM clinical considerations: buprenorphine
treatment of opioid use disorder for individuals using highpotency
synthetic opioids. J Addict Med. 2023;17(6):632-9.
doi: 10.1097/adm.0000000000001202.
29. Button D, Hartley J, Robbins J, Levander XA, Smith NJ,
Englander H. Low-dose buprenorphine initiation in
hospitalized adults with opioid use disorder: a retrospective
cohort analysis. J Addict Med. 2022;16(2):e105-11. doi:
10.1097/adm.0000000000000864.
30. Veazie S, Mackey K, Peterson K, Bourne D. Managing acute
pain in patients taking medication for opioid use disorder: a
rapid review. J Gen Intern Med. 2020;35(Suppl 3):945-53.
doi: 10.1007/s11606-020-06256-5.
31. Lofwall MR, Walsh SL. A review of buprenorphine diversion
and misuse: the current evidence base and experiences from
around the world. J Addict Med. 2014;8(5):315-26. doi:
10.1097/adm.0000000000000045.
32. Han B, Jones CM, Einstein EB, Compton WM. Trends in and
characteristics of buprenorphine misuse among adults in the
US. JAMA Netw Open. 2021;4(10):e2129409. doi: 10.1001/
jamanetworkopen.2021.29409.
33. Azar P, Mathew N, Mahal D, Wong JSH, Westenberg JN,
Schütz CG, et al. Developing a rapid transfer from opioid full
agonist to buprenorphine: “ultrarapid micro-dosing” proof
of concept. J Psychoactive Drugs. 2023;55(1):94-101. doi:
10.1080/02791072.2022.2039814.
)